FDA Brief

Warning letters Drugs

FDA warning letter to

Naturich Cosmetique Labs

High riskIssued Sep 25, 2025Posted Oct 7, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Naturich Cosmetique Labs over inadequate manufacturing controls for over-the-counter topical drugs, including contaminated water and untested ingredients.

What happened

FDA inspected the Garland, Texas, drug manufacturing facility from April 28 to May 2, 2025, and cited significant violations of current good manufacturing practice (CGMP), the FDA rules for drug manufacturing. FDA found the water system was not adequately validated, maintained, sanitized, or monitored, and that the firm did not adequately investigate microbial out-of-limit water results. It also found inadequate process validation, including potency failures, and no adequate identity testing of incoming components such as ethyl alcohol and glycerin.

What FDA found

  1. The firm did not validate, maintain, sanitize, or adequately monitor its water system used to make topical over-the-counter drugs, including products for infants.

    21 CFR 211.100(a)
  2. The firm did not validate its manufacturing processes and released lots with potency variability, including a low-potency acne lotion and a high-potency SPF 30 lotion.

    21 CFR 211.100(a)
  3. The firm did not thoroughly investigate multiple microbial out-of-limit water results, including Enterobacter cloacae, Burkholderia cepacia, and Pseudomonas sp., or establish adequate corrective and preventive actions.

    21 CFR 211.192
  4. The firm did not perform at least one test to confirm each incoming component lot was what it was supposed to be and relied on supplier certificates without establishing their reliability.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  5. The firm did not adequately test ethyl alcohol for methanol or glycerin for diethylene glycol and ethylene glycol before use.

    21 CFR 211.84(d)(1) and 211.84(d)(2)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions, independent assessments, remediation plans, risk assessments, and testing results. FDA also recommends engaging a qualified CGMP consultant.

Who should pay attention

  • brands that buy over-the-counter topical drugs from this contract manufacturer
  • companies sourcing hand sanitizer or skin protectants from contract labs
  • buyers and suppliers of glycerin or ethyl alcohol with high-risk impurity concerns

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk